Lessons learned from the Amsterdam Cohort Studies among people who use drugs: a historical perspective.
HIV
Harm reduction programs
Hepatitis B
Hepatitis C
Infection
Mortality
People who inject drugs
The Netherlands
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
06 01 2021
06 01 2021
Historique:
received:
07
09
2020
accepted:
20
11
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
28
10
2021
Statut:
epublish
Résumé
The Netherlands is well known for its early adoption of harm reduction (HR) programs at the height of its heroin crisis in the 1970s/1980s, including the implementation of the first needle and syringe program worldwide. In this manuscript, we describe how the Amsterdam Cohort Studies (ACS) among people who use drugs (PWUD) was conceived within the context of the Dutch HR approach, including the challenges scientists faced while establishing this cohort. This required striking a balance between public health and individual benefit, solving research dilemmas in the face of uncertainty, developing controversial innovative and cutting-edge interventions, which changed the prevention landscape for PWUD, and using longitudinal cohort data to provide unique insights. Studies from the ACS covering follow-up between 1985 and 2016 revealed that participation in both opioid agonist therapy and needle and syringe programs led to a major decrease in the risk of HIV and hepatitis B and C infection acquisition. ACS data have shown that the observed decrease in incidence also likely included shifts in drug markets and drug culture over time, selective mortality among those with the highest levels of risk behaviour, demographic changes of the PWUD population, and progression of the HIV and HCV epidemics. Moreover, HR programs in the Netherlands provided services beyond care for drug use, such as social support and welfare services, likely contributing to its success in curbing the HIV and viral hepatitis epidemics, increasing access and retention to HIV and HCV care and ultimately decreases in overdose mortality over time. Given the low coverage of HR programs in certain regions, it is unsurprising that continued HIV and HCV outbreaks occur and that transmission is ongoing in many countries worldwide. If we aim to reach the World Health Organization viral hepatitis and HIV elimination targets in 2030, as well as to improve the life of PWUD beyond infection risk, comprehensive HR programs need to be integrated as a part of prevention services, as in the Netherlands. We should use the evidence generated by longstanding cohorts, including the ACS, as a basis for which implementation and improved coverage of integrated HR services can be achieved for PWUD worldwide.
Identifiants
pubmed: 33407562
doi: 10.1186/s12954-020-00444-6
pii: 10.1186/s12954-020-00444-6
pmc: PMC7789277
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2Références
Curr HIV/AIDS Rep. 2018 Jun;15(3):245-254
pubmed: 29796965
AIDS. 2014 Mar 27;28(6):911-8
pubmed: 24401639
Clin Infect Dis. 2013 Aug;57 Suppl 2:S32-8
pubmed: 23884063
Addiction. 1997 Nov;92(11):1457-65
pubmed: 9519489
Public Health Rep. 1992 Nov-Dec;107(6):675-81
pubmed: 1454980
Am J Epidemiol. 1996 Feb 15;143(4):380-91
pubmed: 8633622
J Epidemiol Community Health. 2001 May;55(5):356-63
pubmed: 11297661
Subst Use Misuse. 2006;41(6-7):777-813
pubmed: 16809167
Addiction. 2013 Jun;108(6):1070-81
pubmed: 23347124
AIDS. 2000 Aug 18;14(12):1870-2
pubmed: 10985334
Lancet. 1986 Jun 21;1(8495):1435
pubmed: 2872527
Drug Alcohol Depend. 2005 Aug 1;79(2):231-40
pubmed: 16002032
Am J Epidemiol. 2005 Feb 1;161(3):271-9
pubmed: 15671259
Addiction. 2000 Apr;95(4):591-600
pubmed: 10829334
J Med Virol. 2005 Dec;77(4):509-18
pubmed: 16254983
Lancet Public Health. 2021 May;6(5):e309-e323
pubmed: 33780656
Am J Public Health. 1995 Nov;85(11):1490-1
pubmed: 7485659
Drug Alcohol Depend. 2006 Apr;82 Suppl 1:S29-33
pubmed: 16769442
Lancet HIV. 2019 May;6(5):e315-e324
pubmed: 30981674
Am J Public Health. 2001 May;91(5):774-80
pubmed: 11344886
Addiction. 2018 Mar;113(3):545-563
pubmed: 28891267
AIDS. 1989 Sep;3(9):571-6
pubmed: 2506902
Int J Epidemiol. 1999 Jun;28(3):514-20
pubmed: 10405858
AIDS. 2014 Nov 13;28(17):2589-99
pubmed: 25211439
Eur J Gastroenterol Hepatol. 2011 Jan;23(1):23-31
pubmed: 21042221
Drug Alcohol Depend. 2014 Nov 1;144:141-7
pubmed: 25248472
PLoS One. 2011;6(11):e27555
pubmed: 22110669
Eur J Epidemiol. 2007;22(3):183-93
pubmed: 17334821
Br J Addict. 1990 Oct;85(10):1247-50
pubmed: 2265282
AIDS. 1998;12 Suppl A:S217-30
pubmed: 9633006
Addiction. 2007 Sep;102(9):1454-62
pubmed: 17697278
Am J Public Health. 1992 Apr;82(4):547-51
pubmed: 1312311
Lancet Glob Health. 2017 Dec;5(12):e1208-e1220
pubmed: 29074410
Am J Public Health. 1989 Oct;79(10):1355-7
pubmed: 2782501
AIDS. 1988 Feb;2(1):55-60
pubmed: 3128998
Ned Tijdschr Geneeskd. 1988 Apr 16;132(16):723-8
pubmed: 3374653
Ned Tijdschr Geneeskd. 1984 Feb 11;128(6):272-4
pubmed: 6546786
J Med Virol. 2009 Jul;81(7):1163-9
pubmed: 19475623
AIDS. 2002 Jun 14;16(9):1279-84
pubmed: 12045494
Am J Public Health. 2000 Sep;90(9):1387-8
pubmed: 10983191
Int J Drug Policy. 2015 Feb;26 Suppl 1:S5-11
pubmed: 25727260
Lancet Public Health. 2019 Oct;4(10):e498-e505
pubmed: 31444001
Int J Drug Policy. 2011 May;22(3):210-8
pubmed: 21392958
Drug Alcohol Depend. 2009 Aug 1;103(3):148-54
pubmed: 19443133
BMJ. 2003 Aug 9;327(7410):310
pubmed: 12907482
Am J Epidemiol. 1987 Jun;125(6):1048-57
pubmed: 3495173
Am J Public Health. 1994 Feb;84(2):275-81
pubmed: 8296953